Zayed Abdalla M, Almohaimeed Sulaiman, Eltayeb Amir, Aldosari Hossam A, Alotaibi Turki, Alotaibi Tahani, Alharbi Rawand, Awadallah Yasser, Ancheta Shangrila Joy V, Alasmari Mohamed, Algarni Abeer, Al Ghamdi Eman, Alamrah Shadin
Pediatric Oncology, King Fahad Military Medical Complex, Dhahran, SAU.
Pediatric Nephrology, King Fahad Military Medical Complex, Dhahran, SAU.
Cureus. 2024 Nov 12;16(11):e73532. doi: 10.7759/cureus.73532. eCollection 2024 Nov.
Sickle cell disease (SCD) complications, such as sickle cell nephropathy (SCN), may begin in childhood and progress insidiously to chronic kidney disease in adulthood. In Saudi Arabia (SA), there is a lack of studies evaluating kidney function in children with SCD. This study aims to assess microalbuminuria (MA) as an early marker of renal dysfunction in SCD children living in the Eastern region of SA, to potentially institute appropriate early treatment.
A prospective cross-sectional study was conducted on 114 Saudi children with SCD under the age of 14 years who attended the pediatric hematology clinic for routine follow-up. Demographic and clinical information were collected from the patients and their parents, who provided informed consent. Morning urine samples were collected and tested for the presence of MA using the urinary albumin/creatinine ratio (ACR). Blood samples were also collected for basic laboratory investigations. The prevalence of MA and its correlation with various clinical and laboratory data were analyzed. Additionally, a comparison of clinical characteristics and MA was conducted between children originating from the Southwestern (SW) and Eastern regions of the country, all of whom lived in the Eastern Province.
A total of 114 children with SCD were included in the study. The mean age was 8.8 ± 3.2 years, with a male-to-female ratio of 1.3:1. Based on their region of origin, they were divided into two groups: Eastern (n = 26/114) and SW (n = 88/114). MA was detected in 28 patients (24.6%), with no significant difference in prevalence between the two groups. There was no significant statistical difference in clinical and laboratory data between the groups, except for hemoglobin F (HBF) levels and the use of hydroxyurea (HU). HBF levels were significantly higher in children from the Eastern region, while more SW patients used HU. No correlation was found between MA and any of the studied variables.
MA is common in children with SCD in the Eastern region of SA, with no difference in its prevalence between children of the two different ancestries carrying the Arab-Indian (AI) and African haplotypes. It is not associated with any of the studied clinical variables in this report. Further studies are needed to confirm these findings.
镰状细胞病(SCD)的并发症,如镰状细胞肾病(SCN),可能始于儿童期,并在成年期隐匿进展为慢性肾脏病。在沙特阿拉伯(SA),缺乏对SCD儿童肾功能进行评估的研究。本研究旨在评估微量白蛋白尿(MA)作为沙特东部地区SCD儿童肾功能障碍的早期标志物,以便可能开展适当的早期治疗。
对114名14岁以下前来儿科血液科门诊进行常规随访的沙特SCD儿童进行了一项前瞻性横断面研究。从患者及其父母处收集人口统计学和临床信息,他们均提供了知情同意书。收集晨尿样本,使用尿白蛋白/肌酐比值(ACR)检测MA的存在。还采集血样进行基础实验室检查。分析了MA的患病率及其与各种临床和实验室数据的相关性。此外,对来自该国西南部(SW)和东部地区且均居住在东部省份的儿童的临床特征和MA进行了比较。
本研究共纳入114名SCD儿童。平均年龄为8.8±3.2岁,男女比例为1.3:1。根据其原籍地区,他们被分为两组:东部组(n = 26/114)和SW组(n = 88/114)。28例患者(24.6%)检测到MA,两组患病率无显著差异。除血红蛋白F(HBF)水平和羟基脲(HU)的使用外,两组间临床和实验室数据无显著统计学差异。东部地区儿童的HBF水平显著更高,而更多SW患者使用HU。未发现MA与任何研究变量之间存在相关性。
MA在沙特东部地区的SCD儿童中很常见,携带阿拉伯 - 印度(AI)和非洲单倍型的两个不同血统儿童之间的患病率无差异。在本报告中,它与任何研究的临床变量均无关联。需要进一步研究来证实这些发现。